These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Cyclophosphamide and horse anti-thymocyte globulin versus fludarabine, reduced cyclophosphamide and rabbit anti-thymocyte globulin conditioning regimen for allogeneic hematopoietic stem cell transplantation from matched sibling donors in patients with acquired aplastic anemia. Ben Abdeljelil N; Ben Yaiche I; Ouerghi R; Torjemane L; Belloumi D; Turki I; Mekni S; Kanoun RY; Ben Othman T; Ladeb S Expert Rev Hematol; 2024 Aug; 17(8):527-538. PubMed ID: 39011776 [TBL] [Abstract][Full Text] [Related]
23. [Comparison of unrelated cord blood transplantation and HLA-identical sibling peripheral blood stem cell transplantation for the treatment of adult hematological malignancies]. Zheng CC; Zhu XY; Tang BL; Tong J; Zhang XH; Zhang L; Song KD; Geng LQ; Liu HL; Sun ZM Zhonghua Xue Ye Xue Za Zhi; 2017 Aug; 38(8):673-679. PubMed ID: 28954345 [No Abstract] [Full Text] [Related]
24. Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial. Zu Y; Li Z; Gui R; Liu Y; Zhang Y; Yu F; Zhao H; Fu Y; Zhan X; Wang Z; Xing P; Wang X; Wang H; Zhou J; Song Y Bone Marrow Transplant; 2022 Oct; 57(10):1573-1580. PubMed ID: 35840747 [TBL] [Abstract][Full Text] [Related]
25. Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia. Huang Z; Yan H; Teng Y; Shi W; Xia L Front Immunol; 2022; 13():1017850. PubMed ID: 36458000 [TBL] [Abstract][Full Text] [Related]
26. Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide-based regimen for prevention of graft-versus-host disease in haploidentical peripheral blood stem cell transplantation for pediatric patients with hematologic malignancies. Du Y; Zhang Y; Xu X; Cai Y; Wei Y; Huang C; Yang J; Qiu H; Niu J; Zhou K; Xia X; Shen C; Tong Y; Dong B; Wan L; Song X Ann Hematol; 2024 Sep; 103(9):3765-3774. PubMed ID: 38981923 [TBL] [Abstract][Full Text] [Related]
27. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963 [TBL] [Abstract][Full Text] [Related]
28. Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide as an Effective Regimen for Prophylaxis of Graft Li T; He Q; Yang J; Cai Y; Huang C; Xu X; Qiu H; Niu J; Zhou K; Zhang Y; Xia X; Wei Y; Shen C; Ding X; Tong Y; Wan L; Song X Cell Transplant; 2022; 31():9636897221139103. PubMed ID: 36433646 [TBL] [Abstract][Full Text] [Related]
29. Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological malignancies. Chen TT; Lin CC; Lo WJ; Hsieh CY; Lien MY; Lin CH; Lin CY; Bai LY; Chiu CF; Yeh SP Int J Hematol; 2022 Apr; 115(4):525-533. PubMed ID: 35226308 [TBL] [Abstract][Full Text] [Related]
30. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial. Zhang W; Gui R; Zu Y; Zhang B; Li Z; Zhang Y; Wang X; Guo S; Zhan X; Fu Y; Song Y; Zhou J Br J Haematol; 2023 Jan; 200(2):210-221. PubMed ID: 36200642 [TBL] [Abstract][Full Text] [Related]
31. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission. Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421 [TBL] [Abstract][Full Text] [Related]
33. Impact of Low-Dose rATG Prior to Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: Reduced Risk of Chronic Graft-versus-Host Disease and Improved Survival Outcomes. Song ZY; Ren HY; Dong YJ; Li Y; Yin Y; Sun YH; Wang Q; Xu WL; Liu W; Ou JP; Liang ZY Cancer Manag Res; 2020; 12():12287-12300. PubMed ID: 33311999 [TBL] [Abstract][Full Text] [Related]
34. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Theurich S; Fischmann H; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Scheid C; Skoetz N; von Bergwelt-Baildon M Cochrane Database Syst Rev; 2012 Sep; (9):CD009159. PubMed ID: 22972135 [TBL] [Abstract][Full Text] [Related]
35. Retrospective Comparison of Efficacy and Safety of Rabbit Anti-Thymocyte Globulin and Porcine Anti-Lymphocyte Globulin in Patients With Acquired Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation From Matched Sibling Donors. Zhang Y; Chen X; Li L; Li Y; Lin L; Cao Y; Wang N; Yang D; Pang A; Zhang R; Ma Q; Zhai W; He Y; Wei J; Jiang E; Han M; Zhang Y; Feng S Front Immunol; 2022; 13():889784. PubMed ID: 35784311 [TBL] [Abstract][Full Text] [Related]
36. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate. Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856 [TBL] [Abstract][Full Text] [Related]
37. Post-Transplant Cyclophosphamide and Thymoglobulin, a Graft-Versus-Host Disease Prophylaxis in Matched Sibling Donor Peripheral Blood Stem Cell Transplantations. Kunacheewa C; Owattanapanish W; Jirabanditsakul C; Issaragrisil S Cell Transplant; 2020; 29():963689720965900. PubMed ID: 33035116 [TBL] [Abstract][Full Text] [Related]
38. [Haploidentical donor peripheral blood stem cell transplantation using third-party cord blood compared with matched unrelated donor transplantation for patients with hematologic malignancies]. Ma X; Chen Y; Liu Y; Cheng TT; Chen X; Zeng C; Hua J; Wang SY; Xu YJ Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):141-147. PubMed ID: 38604790 [No Abstract] [Full Text] [Related]
39. Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study. Chang YJ; Wu DP; Lai YR; Liu QF; Sun YQ; Hu J; Hu Y; Zhou JF; Li J; Wang SQ; Li W; Du X; Lin DJ; Ren HY; Chen FP; Li YH; Zhang X; Huang H; Song YP; Jiang M; Hu JD; Liang YM; Wang JB; Xiao Y; Huang XJ J Clin Oncol; 2020 Oct; 38(29):3367-3376. PubMed ID: 32650683 [TBL] [Abstract][Full Text] [Related]